Imiquimod-d9(Synonyms: R 837-d9)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Imiquimod-d9 (Synonyms: R 837-d9)

Imiquimod-d9 是 Imiquimod 氘代物。Imiquimod (R 837) 是一种 toll 样受体7 (TLR7) 激动剂，作为一种免疫反应修饰剂。Imiquimod 在体内表现出抗病毒和抗肿瘤作用。Imiquimod 可用于外生殖器、肛周疣、癌症和 COVID-19 的研究。

Imiquimod-d9(Synonyms: R 837-d9)

Imiquimod-d9 Chemical Structure

CAS No. : 2712126-48-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

249.36

Formula

C14H7D9N4
CAS 号

2712126-48-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Athina Angelopoulou, et al. Imiquimod – A toll like receptor 7 agonist – Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.

    [3]. Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60.

    [4]. Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46.

    [5]. Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务